evaluation

Evaluation of contributions to

congresses and seminars is seen by the ESC as a tool of quality control.

Evaluation can also contribute to the continuation of high standards of

congresses and seminars and where possible make improvements for the future.

Therefore the ESC asked participants

of the 7^th Congress of the European Society for contraception, “Changing

attitudes to Contraception and Reproductive Health”, which was held in

Genova, 10-13^th of April 2002, to fill in an evaluation form and score

the sessions attended. A total of 40 contributions were

evaluated, 241 forms were fit for evaluation. The number of hits per

contribution varied from 42 to 198. This means that relative to the total number

of participants the number of evaluation forms is rather low. On the other hand the participants in

general were very satisfied with the quality of the contributions. In a scale

from 1 ‘poor’ to 5 ‘excellent’ the average score was 4,2! The single contribution which scored

highest, was the closing session ‘Future contraception form research to

practice’ which scored an excellent 4,5. Other topics, which scored very high,

were the contributions on sexual transmitted viral infections and the meet the

expert’s session on sexual dysfunction and contraception. All the main session speakers scored

4 or more, but even of the contributions, which scored a little lower, all were

at least satisfactory or higher. The ESC can be very content with this

evaluation. A point of improvement the next time will be to convince the

participants how important it is to fill in these evaluation forms.

 

Evaluation of the congress speakers
Theme of lecture	Session	*	**
Contraception and Society	Opening Lecture	4,2	193
Steroid receptors	Main Session I From Biology to Contraception	4,1	191
New progestins	Main Session I From Biology to Contraception	4,1	198
Implantation	Main Session I From Biology to Contraception	4,1	195
Legislation	Session 1: Abortion situation in Europe	3,9	109
Statistical information	Session 1: Abortion situation in Europe	3,7	109
Changing attitudes towards abortion	Session 1: Abortion situation in Europe	3,9	118
Long acting methods	Meet the Experts	3	80
Psychological aspects	Meet the Experts	3,8	68
The role of the non medical professionals in contraception	Meet the Experts	3,9	63
OC use and endometriosis	Meet the Experts	3,8	42
Contraception in PCO patients	Meet the Experts	4	81
Spermicides	Meet the Experts	3,5	52
Breast, ovary, endometrium and cervix	Session 4: Cancer and contraception	3,5	168
IUD	Workshops	4	69
Adolescent forum	Workshops	4	90
The Web as a teacher in the contraceptive field	Workshops	3,3	48
Continuation and compliance of contraceptive use	Session 6: What do women want?	3,8	113
Counselling in contraception	Session 6: What do women want?	4,1	127
Anti-ovulatory effects of progestin preparations	Main Session II Progestin-only contraception	4,2	181
Clinical profile of progestin contraception	Main Session II Progestin-only contraception	4,1	153
Mode of delivery systems (impact on acceptability)	Main Session II Progestin-only contraception	4	130
Male contraception with androgen plus progestin	Session 2: Male contraception	4,1	126
Other possibilities	Session 2: Male contraception	4	108
Psychological aspects	Session 2: Male contraception	3,8	109
Adolescent contraception	Meet the Experts	4,2	69
Non-bleeding OC regimens	Meet the Experts	4,2	49
Early medical abortions	Meet the Experts	3,9	46
Non-viral STD	Meet the Experts	3,9	45
Fertility regulation in the perimenopause	Meet the Experts	4,2	53
Sexual dysfunction and contraception	Meet the Experts	4,3	54
Clinical aspects	Session 5: Emergency contraception	4,2	87
Over the counter	Session 5: Emergency contraception	4,1	67
Evidence based contraceptive practice	Workshops	4	59
Hepatitis	Main Session III Sexual transmitted viral infections	4,1	72
HIV	Main Session III Sexual transmitted viral infections	4,3	78
HPV	Main Session III Sexual transmitted viral infections	4,3	80
Biologic effects	Session 3: Oral contraception and CVD	4,1	75
Epidemiologic effects	Session 3: Oral contraception and CVD	4	72
Future contraception, from research to practice	Main Session IV	4,5	47
LEGEND:
* score on 5 scale: 5 = excellent, 4 = good, 3 = average, 2 = below average, 1 = poor
** number of hits = number of persons who evaluated this speaker (total of participating persons to evaluation: 241)

(back to

news) (back to ESC congress)

home